COMPUESTOS HETEROAROMATICOS Y SU USO COMO LIGANDOS DE DOPAMINA D1

SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R1 Y R2 SON CADA UNO H, HALOGENO, CN, ALQUILO C1-C6, ENTRE OTROS; R3 Y R4 SON CADA UNO H, OH, HALOGENO, NH2, ENTRE OTROS; Q1 ES UN HETEROARILO DE 5 A 10 MIEMBROS, HETEROCICLOALQUILO DE 4 A 12 MIEMBROS O FENILO; L1 ES O, S, C(=O), CH(OH), ENTRE OTROS; T1 E...

Full description

Saved in:
Bibliographic Details
Main Authors MENTE, Scot Richard, EFREMOV, Ivan Viktorovich, ZHANG, Lei, GRAY, David Lawrence Firman, DOUNAY, Amy Beth, SUBRAMANYAM, Chakrapani, DAVOREN, Jennifer Elizabeth
Format Patent
LanguageSpanish
Published 17.03.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R1 Y R2 SON CADA UNO H, HALOGENO, CN, ALQUILO C1-C6, ENTRE OTROS; R3 Y R4 SON CADA UNO H, OH, HALOGENO, NH2, ENTRE OTROS; Q1 ES UN HETEROARILO DE 5 A 10 MIEMBROS, HETEROCICLOALQUILO DE 4 A 12 MIEMBROS O FENILO; L1 ES O, S, C(=O), CH(OH), ENTRE OTROS; T1 ES H, OH, HALOGENO, CN, ALQUILO C1-C2; X1 ES O, S, NH, N(ALQUILO C1-C4), ENTRE OTROS; X2 ES N O C-T2; X3 ES N O C-T3; X4 ES N O C-T4, DONDE T2, T3 Y T4 SON CADA UNO H, OH, CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (+)-1,5-DIMETIL-6-[2-METIL-4-(TIENO[3,2-d]PIRIMIDIN-4-ILOXI)FENIL]PIRIMIDIN-2,4(1H,3H)-DIONA; 4,6-DIMETIL-5-[2-METIL-4-([1,2]TIAZOLO[5,4-c]PIRIDIN-7-ILOXI)FENIL]PIRIDAZIN-3(2H)-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON LIGANDOS DE DOPAMINA D1 SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, DEFICIENCIA COGNITIVA, ENFERMEDAD DE PARKINSON, ANSIEDAD The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
AbstractList SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R1 Y R2 SON CADA UNO H, HALOGENO, CN, ALQUILO C1-C6, ENTRE OTROS; R3 Y R4 SON CADA UNO H, OH, HALOGENO, NH2, ENTRE OTROS; Q1 ES UN HETEROARILO DE 5 A 10 MIEMBROS, HETEROCICLOALQUILO DE 4 A 12 MIEMBROS O FENILO; L1 ES O, S, C(=O), CH(OH), ENTRE OTROS; T1 ES H, OH, HALOGENO, CN, ALQUILO C1-C2; X1 ES O, S, NH, N(ALQUILO C1-C4), ENTRE OTROS; X2 ES N O C-T2; X3 ES N O C-T3; X4 ES N O C-T4, DONDE T2, T3 Y T4 SON CADA UNO H, OH, CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (+)-1,5-DIMETIL-6-[2-METIL-4-(TIENO[3,2-d]PIRIMIDIN-4-ILOXI)FENIL]PIRIMIDIN-2,4(1H,3H)-DIONA; 4,6-DIMETIL-5-[2-METIL-4-([1,2]TIAZOLO[5,4-c]PIRIDIN-7-ILOXI)FENIL]PIRIDAZIN-3(2H)-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON LIGANDOS DE DOPAMINA D1 SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, DEFICIENCIA COGNITIVA, ENFERMEDAD DE PARKINSON, ANSIEDAD The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
Author DOUNAY, Amy Beth
SUBRAMANYAM, Chakrapani
GRAY, David Lawrence Firman
ZHANG, Lei
MENTE, Scot Richard
EFREMOV, Ivan Viktorovich
DAVOREN, Jennifer Elizabeth
Author_xml – fullname: MENTE, Scot Richard
– fullname: EFREMOV, Ivan Viktorovich
– fullname: ZHANG, Lei
– fullname: GRAY, David Lawrence Firman
– fullname: DOUNAY, Amy Beth
– fullname: SUBRAMANYAM, Chakrapani
– fullname: DAVOREN, Jennifer Elizabeth
BookMark eNrjYmDJy89L5WRwdPb3DQh1DQ7xD1bwcA1xDfJ3DPL3dQzxdAYKRCoEhyqEBvsrABX5K_h4ujv6uQCFXVwVXPwDHH09_RwVXAx5GFjTEnOKU3mhNDeDoptriLOHbmpBfnxqcUFicmpeakl8gKuRgaG5gYGBhaOhMTFqAPAvLH0
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID PE20170008A1
GroupedDBID EVB
ID FETCH-epo_espacenet_PE20170008A13
IEDL.DBID EVB
IngestDate Fri Jul 19 13:55:43 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Spanish
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_PE20170008A13
Notes Application Number: PE2016002125
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170317&DB=EPODOC&CC=PE&NR=20170008A1
ParticipantIDs epo_espacenet_PE20170008A1
PublicationCentury 2000
PublicationDate 20170317
PublicationDateYYYYMMDD 2017-03-17
PublicationDate_xml – month: 03
  year: 2017
  text: 20170317
  day: 17
PublicationDecade 2010
PublicationYear 2017
RelatedCompanies PFIZER INC
RelatedCompanies_xml – name: PFIZER INC
Score 3.0757868
Snippet SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R1 Y R2 SON CADA UNO H, HALOGENO, CN, ALQUILO C1-C6, ENTRE OTROS; R3 Y R4 SON CADA UNO H, OH, HALOGENO, NH2, ENTRE...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title COMPUESTOS HETEROAROMATICOS Y SU USO COMO LIGANDOS DE DOPAMINA D1
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170317&DB=EPODOC&locale=&CC=PE&NR=20170008A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEL8QNOqbokbxIzUxe1tkbNDtgZjSFsG4dWGbwSfCvhJ9ACIz_vveJogv-tbeNU3b5Ne7tne_Atw6ZmJSIzZ1u23lupUmVJ_RrKWjsU9anXbenVUEpq7XHUbW46QzqcHbJhem4gn9rMgREVEJ4r2o9uvl9hJLVLGVq7v4FUWL-0HYE9r6dGyUbOxUE_2e9JVQXOO850vNG3_r0N4xPCntoBtNSzTI536ZlbL8bVIGh7DrY2_z4ghq2aoB-3zz81oD9tz1gzcW19hbHQPjyvUjGYQqIEOJXqhiY-WycMRR8EKCiESBIthIkafRA_MEioUkQvnMHXmMCOMEbgYy5EMdxzL9mfjUl9thm6dQny_m2RmQFHHnGJ3MLlk8Z-3cyY3UdqzUyVt2bCf0HJp_99P8T3kBB2WljLEy6CXUi_eP7AqNbhFfV6v1BT03fsg
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEL8QNOKbokbxqyZmb4uMDbY9EFPW4qZsXdhm8Imwr0QfgMiM_763CeKLvjV3zaVt8utd27tfAW5NNVF1JVZlo6PlspYmujzTs7aMzj5pdzt5b1YRmLpez460x0l3UoO3TS1MxRP6WZEjIqISxHtR7dfL7SUWq3IrV3fxK4oW98Owz6T16Vgp2dh1iQ363BdMWJJl9X0ueeNvHfo7iielHQyx9RIN_HlQVqUsf7uU4QHs-mhtXhxCLVs1oWFtfl5rwp67fvDG5hp7qyOglnD9iAehCIjNMQoVdCxcGjoWCl5IEJEoEAQ7CTJyHqjHUMw4YcKnruNRwpRjuBny0LJlHMv0Z-JTn2-HrZ5Afb6YZ6dAUsSdqXQzo2TxnHVyM1dSw9RSM28bsZHoZ9D6207rP-U1NOzQHU1Hjvd0Dvulosy3UvQLqBfvH9klOuAivqpW7gta4YG7
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=COMPUESTOS+HETEROAROMATICOS+Y+SU+USO+COMO+LIGANDOS+DE+DOPAMINA+D1&rft.inventor=MENTE%2C+Scot+Richard&rft.inventor=EFREMOV%2C+Ivan+Viktorovich&rft.inventor=ZHANG%2C+Lei&rft.inventor=GRAY%2C+David+Lawrence+Firman&rft.inventor=DOUNAY%2C+Amy+Beth&rft.inventor=SUBRAMANYAM%2C+Chakrapani&rft.inventor=DAVOREN%2C+Jennifer+Elizabeth&rft.date=2017-03-17&rft.externalDBID=A1&rft.externalDocID=PE20170008A1